Ubrogepant to Treat Acute Migraine in Adults [PDF]
Neurology International, 2021 Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States. Medical treatment of mild to moderate migraines include non-prescription non-steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-
Amber N. Edinoff +12 more
doaj +5 more sources
Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial [PDF]
Clinical and Translational ScienceUbrogepant (Ubrelvy), a CGRP receptor antagonist, is approved for acute treatment of migraine with or without aura in adults. Because ubrogepant treats a neurological condition, it is of interest to know central nervous system exposure.
Ramesh R. Boinpally, Joel M. Trugman
doaj +3 more sources
Ubrogepant in the Acute Management of Migraine: A Narrative Review
Journal of Pain Research, 2021 Chia-Chun Chiang,1 Juliana H VanderPluym2 1Department of Neurology, Mayo Clinic, Rochester, MN, USA; 2Department of Neurology, Mayo Clinic, Scottsdale, AZ, USACorrespondence: Juliana H VanderPluym Email vanderpluym.juliana@mayo.eduAbstract: Ubrogepant is
Chia-Chun Chiang
exaly +7 more sources
Milk and Plasma Pharmacokinetics of Single-Dose Ubrogepant in Healthy Lactating Women [PDF]
HeadacheAbstract Objective The objectives of this study were to evaluate the safety, plasma and milk pharmacokinetics, excretion in breast milk, and the relative infant dose of ubrogepant following a single oral dose. Background
Ramesh R Boinpally, Joel M Trugman
exaly +4 more sources
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans [PDF]
Headache, 2020 Objective To evaluate the potential for pharmacokinetic interaction and the safety and tolerability when ubrogepant and sumatriptan are coadministered in a Phase 1 study in healthy participants, and to inform the safety and tolerability of ubrogepant alone and in combination with triptans in Phase 3 trials in ...
Abhijeet Jakate +2 more
exaly +3 more sources
Efficacy, safety, and tolerability of ubrogepant in the treatment of acute migraine among migraine patients in Hail City, Saudi Arabia: A retrospective case [PDF]
Journal of Family Medicine and Primary CareMigraines represent a significant health burden globally and are particularly prevalent in Saudi Arabia, with rates exceeding the global average. Effective management of acute migraine attacks is crucial for improving patient outcomes.
Walid Alesefir +8 more
doaj +2 more sources
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males [PDF]
Clinical and Translational Science, 2020 Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were ...
Wendy Ankrom +13 more
doaj +3 more sources
Gepants: targeting the CGRP pathway for migraine relief [PDF]
Frontiers in PharmacologyBackgroundCalcitonin gene–related peptide (CGRP) receptor antagonist (collectively known as gepant) have emerged as effective therapies for both acute migraine treatment and preventive management.
Bernadetta Jakubowska +2 more
doaj +2 more sources
Ubrogepant for the Treatment of Migraine
New England Journal of Medicine, 2019 Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a ...
Jessica Ailani +2 more
exaly +3 more sources
Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis [PDF]
Frontiers in NeurologyBackgroundA range of pharmacologic options is available for acute migraine treatment, yet the efficacy and safety of commonly used over-the-counter (OTC) therapies relative to newer prescription agents remain unclear. Given the scarcity of direct head-to-
Ashoke Mitra +4 more
doaj +2 more sources